Medicine and Dentistry
Adenocarcinoma
7%
Adjuvant Therapy
14%
Bevacizumab
10%
Biological Marker
6%
Body Mass Index
11%
Brachytherapy
9%
Cancer
22%
Carboplatin
13%
Carcinosarcoma
18%
Cervical Cancer
28%
Chemoradiotherapy
7%
Cisplatin
7%
Clinical Trial
9%
Combination Therapy
6%
Connective Tissue Cancer
7%
Disease Free Survival
7%
Diseases
40%
DNA Mismatch Repair
12%
Endometrium Carcinoma
22%
Fallopian Tube
10%
Female Genital Tract Cancer
12%
Fluorodeoxyglucose
7%
Gynecological Oncology
48%
Gynecology
7%
Hazard Ratio
11%
Hereditary Nonpolyposis Colorectal Cancer
7%
Hysterectomy
6%
Intensity Modulated Radiation Therapy
9%
Kaplan Meier Method
8%
Krukenberg Tumor
13%
Lymph Node
7%
Lymph Node Metastasis
6%
Malignant Neoplasm
32%
Metastatic Carcinoma
12%
Microsatellite Instability
13%
Multivariate Analysis
6%
Neoplasm
46%
Oncology
26%
Ovarian Cancer
39%
Overall Survival
44%
Paclitaxel
14%
Pelvis
15%
Positron Emission Tomography
16%
Progression Free Survival
19%
Radiation Therapy
17%
Recurrent Disease
27%
Recurrent Ovarian Cancer
7%
Surgery
6%
Uterine Cancer
100%
Uterine Cervix Carcinoma
7%
Keyphrases
Adjuvant Therapy
13%
Bevacizumab
13%
Body Mass Index
9%
Brachytherapy
8%
Cancer Patients
8%
Carboplatin
16%
Carboplatin-paclitaxel
7%
Cervical Cancer
21%
Cervical Cancer Patients
8%
Cervical Carcinoma
9%
Chemotherapy
30%
Cisplatin
12%
Clinical Outcomes
8%
Confidence Interval
16%
Disease-free Survival
7%
Dostarlimab
7%
Endometrial Cancer
64%
Endometrial Carcinoma
14%
Endometrioid
13%
Endometrioid Endometrial Cancer
10%
Epithelial Ovarian Cancer
8%
Fallopian Tube
8%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
10%
Group Studies
20%
Gynecologic Malignancies
7%
Gynecologic Oncology
23%
Gynecologic Oncology Group
28%
Gynecological Cancer
9%
Hazard Ratio
15%
Immunohistochemistry
7%
Intensity-modulated Radiation Therapy
8%
Microsatellite Instability-high (MSI-H)
17%
Mismatch Repair
10%
NRG Oncology
29%
Oncology Patients
13%
Ovarian Cancer
30%
Overall Survival
42%
Paclitaxel
14%
Phase II Trial
7%
Positron Emission Tomography
9%
Primary Peritoneal Cancer
8%
Progression-free Survival
17%
Radiation Therapy
9%
Recurrent Endometrial Cancer
21%
Recurrent Ovarian Cancer
9%
Survival Outcomes
8%
Tumor
28%
Uterine Cancer
7%
Uterine Carcinosarcoma
14%
Uterine Serous Carcinoma
13%